|

Mesothelioma Patient Registry May Finally Be a Reality

mesothelioma patient registryThe United States may finally get a mesothelioma patient registry to help collect and track vital information about this deadly disease. 

New York Congressman John Katko has reintroduced a bill he first brought before Congress six years ago. The Mary Jo Lawyer Spano Mesothelioma Patient Registry Act would establish the first national registry for asbestos cancer. 

Registries like this exist for many other kinds of cancer. But malignant mesothelioma is very rare. This makes it even harder for doctors and scientists to access the information they need to understand and treat this cancer. 

Experts from the CDC, the National Institute for Occupational Safety and Health (NIOSH), and several top US cancer centers have been calling for a mesothelioma patient registry for years. The new bill provides hope that it may actually happen this time. 

Bill’s Namesake a Victim of the Legacy of Asbestos

The new mesothelioma patient registry bill is named for a New York woman who died of mesothelioma in 2014. Her sister, Meg Meccariello, died of the same rare cancer a year later. 

Although the two women never worked with asbestos, they are believed to have been exposed to the toxin on the work clothes of their father, Charles Lawyer. He was likely exposed to asbestos in the elevator company where he worked. Charles Lawyer also died of mesothelioma.

The mesothelioma patient registry created by Rep. Katko’s legislation would collect voluntary health information from mesothelioma patients around the country. The information could then be used to support and enhance mesothelioma research.

“I’m reintroducing a bill inspired by a Central New York native who lost her four year battle with mesothelioma in 2014,” Rep. Katko said in a statement. “Sadly, many Americans, including hundreds of 9/11 first responders, are still suffering from this terrible disease. By creating a national registry, my bill will help us take meaningful steps to understand, treat, and eventually cure mesothelioma.”

The bill is co-sponsored by Katko’s fellow New York representatives, Antonio Delgado and Kathleen Rice. 

How a Mesothelioma Patient Registry Could Help

Malignant mesothelioma is difficult to study because it is so rare. A national mesothelioma patient registry is a centralized place to hold patient information. It would house details about tumors, diagnosis, symptoms, and exposure history. Researchers and doctors could use the information to improve mesothelioma care. 

Some cancer centers have started similar databases. The National Mesothelioma Virtual Bank at the Icahn School of Medicine at Mount Sinai is an example. It collects and saves mesothelioma tumor samples for research. But it is much smaller and more limited than a national database would be. 

According to Rep. Katko’s office, a CDC-based national mesothelioma patient registry would help in several ways. It would:

  • Support the development and revision of treatment standards
  • Allow for the sharing of information between mesothelioma doctors 
  • Set up benchmarks for mesothelioma clinics to meet

The new registry will also allow patients to see which cancer centers provide the best care for mesothelioma patients. All of these things are currently more difficult for mesothelioma patients than they are for many other types of cancer patients because the disease is so rare and no registry exists. 

Only about 3,000 people are diagnosed with mesothelioma in the US each year. Almost all of them have lived or worked around asbestos. 

Source:

Rep. Katko Reintroduces Bill to Create National Mesothelioma Patient Registry, November 5, 2021, Press release, Rep. Katko’s website, https://katko.house.gov/media-center/press-releases/rep-katko-reintroduces-bill-create-national-mesothelioma-patient

H.R. 5869 (IH) – Mary Jo Lawyer Spano Mesothelioma Patient Registry Act of 2021, https://www.govinfo.gov/app/details/BILLS-117hr5869ih

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • |

    Mesothelioma Case Shows Danger of Accidental Asbestos Exposure

    A mesothelioma case in Birmingham, England is a dramatic illustration of the very real danger of hidden asbestos. The widow of a physician who died of mesothelioma last year at the age of 51 claims her husband was exposed to asbestos just walking to and from his medical classes. Monisha Coelho believes that exposed asbestos insulation in the underground hallways that connect the University of Birmingham to buildings on the Queen Elizabeth Hospital campus triggered Dr. Ian Pardoe’s mesothelioma. In an article in the Birmingham Mail, Coelho explained how her husband decided how and where the deadly exposure had occurred. “Ian thought long and hard about where he might have come into contact with asbestos,” Coelho told the paper. “He…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…